Catalyst Wire Dossier Catalyst Wire Dossier

ARX-F01

sufentanil · Talphera, Inc
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARX-F01, covering 2014-02-17 to 2014-02-17. Get the full timeline:

Most recent: Clinical Trial Update: A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement [Phase 2]

See pricing